Background The functions of many proteins are tightly regulated with a complex array of cellular functions including ubiquitination. In cancer cells, aberrant ubiquitination may promote the activity of oncogenic pathways with subsequent tumour progression. Kelch-like family member 7 (KLHL7) is involved in the regulation of ubiquitination and may play a role in breast cancer (BC). Present study aims to evaluate the biological and clinical usefulness of KLHL7 in BC utilising large well-characterised cohorts with long-term follow-up. Methods The relationships between KLHL7 gene copy number alteration (CNA) and mRNA expression and clinicopathological variables and clinical outcomes were evaluated in 1980 patients from the METABRIC BC cohort. Prognostic significance of KLHL7 mRNA was validated using the Breast Cancer Gene-Expression Miner v4.0 datasets (n = 5206). KLHL7 protein expression was assessed using immunohistochemistry in a large annotated series of early-stage BC (n = 917) with long-term follow-up. Results KLHL7 CNA was significantly correlated with its mRNA expression. KLHL7 mRNA expression was higher in luminal B and basal-like molecular subtypes and in higher grade tumours. Increased KLHL7 protein expression was significantly correlated with features of aggressive phenotype including lymphovascular invasion, high histological grade, hormonal receptor negativity, high PIK3CA and p53 expression. Outcome analysis showed that high KLHL7 expression is an independent predictor of shorter survival (p = 0.0011). Conclusions KLHL7 appears to play an important role in BC progression. High KLHL7 protein expression identified a subgroup of BC with aggressive behaviour and provided independent prognostic information.
Introduction
Advances in early detection, diagnosis and refinement of prognostic and therapy prediction have led to improvement of the outcome of invasive breast cancer; however, approximately 20% of early-stage breast cancer patients still experience recurrence and metastasis [1, 2] . Identification 
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of genes significantly associated with tumour progression providing potential therapeutic values remains as one of the main goals of breast cancer research. The functions of many proteins are controlled by ubiquitination [3, 4] , and in cancer cells, abnormal ubiquitination may promote the activity of oncogenic pathways [5, 6] , enhance tumour proliferation, migration, invasion, angiogenesis, epithelial-mesenchymal transition and metastasis [7, 8] . Kelch-like family member 7 (KLHL7), which is a member of the Kelch protein family associated with the development of retinitis pigmentosa [9, 10] , forms a ubiquitin ligase complex by binding to the BTB and BACK domains of Cullin3 (CUL3) [10, 11] . This binding facilitates proteasome degradation of target proteins by enhancing E2 or E3 ligase activity and polyubiquitination [10] [11] [12] . KLHL7 is considered to be crucial for regulating the protein homeostasis and its aberrant expression has also been associated with cancer cell proliferation [13] [14] [15] [16] . However, the role of KLHL7 in breast cancer has not been established.
In this study, we investigated the biological and clinical significance of KLHL7 in breast cancer at the genetic transcriptomic and protein levels. KLHL7 copy number alterations (CNA) and mRNA expression as well as KLHL7 protein expression assessed using immunohistochemistry were correlated with clinicopathological features and outcome using large well-characterised cohorts of early-stage breast cancer.
Materials and methods

KLHL7 gene copy number and mRNA expression
The Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset, containing 1980 invasive breast cancers [17, 18] , was explored for genomic/transcriptomic profiling of KLHL7. In the METABRIC study, DNA and RNA extracted from primary tumour samples were hybridised using Affymetrix SNP 6.0 arrays (Affymetrix, Inc., Santa Clara, USA) and Illumina Human HT-12 v3 platforms (Illumina, Inc., San Diego, USA). All patients were treated uniformly. Oestrogen receptor (ER)-positive breast cancer patients with lymph node negative were not offered adjuvant chemotherapy. ER-negative or lymph node-positive patients were treated with adjuvant chemotherapy. No human epithelial growth factor 2 (HER2)-positive patients received therapy with trastuzumab. None of the patients included in the study received neoadjuvant treatment.
The prognostic value of KLHL7 mRNA expression was further evaluated using the Breast Cancer Gene-Expression Miner v4.0 (bc-GenExMiner v4.0) database which includes 5861 breast cancer patients [19] .
KLHL7 protein expression
KLHL7 protein expression was assessed in large (n = 917) cohort of early-stage breast cancer from surgically treated patients presented to Nottingham City Hospital, UK between 1989 and 1998. Tissue microarray (TMA) sections were stained using specific anti-KLHL7 antibody (see below). No patients underwent neoadjuvant treatment before initial breast surgery. In this study, 917 cases were informative for the biomarker expression. Lymphovascular invasion (LVI) was evaluated by haematoxylin and eosin staining and immunostaining for CD34 or D2-40 as previously described [20] . Patient characteristics were shown in Supplementary  Table 1 . Data on ER, progesterone receptor (PR), HER2, Ki67, phosphatidylinositol 3-kinase (PIK3CA), p53 and phospho-Akt1 (pAkt) were available and were assessed as previously described [21] [22] [23] [24] [25] [26] . ER-positive/HER2-negative breast cancer patients with PR-positive and low Ki67 staining (labelling index of ≤ 10%) were classified as luminal A-like type; other ER-positive patients were classified as luminal B-like type. Patients who were ER-positive and/or PR-positive and HER2-positive were defines as luminal-HER2 [27] .
The specificity of KLHL7 antibody (HPA029491, Merck, Germany) was confirmed using Western blotting and MCF-7 and Jurkat cell lines (The American Type Culture Collection; Rockville, MD, USA). This showed primary antibody specificity with a single band observed at approximately 70 kDa in both cell lines (Supplementary Fig. 2 ).
KLHL7 protein expression was characterised immunohistochemically (IHC) in 15 full-face breast cancer tissue sections prior to TMA application. IHC assays were performed using Novolink Max Polymer Detection System (RE7280-k, Leica, Newcastle, UK). The anti-KLHL7 primary antibody was diluted 1:100 in Bond Primary Antibody Diluent (Leica, Germany). A polyclonal rabbit anti-human beta-2-microglobulin antibody (diluted 1:2000; Dako, Glostrup, Denmark) was used as a positive staining control. Diaminobenzidine tetrahydrochloride (Novolink DAB substrate buffer plus) was used as the chromogen; sections were counterstained with Meyer's haematoxylin for 6 min.
Immunostained TMA sections were digitally scanned into high-resolution digital images (NanoZoomer, Hamamatsu Photonics, Tokyo, Japan) and viewed using Aperio Image Scope (Aperio Technologies, Milton Keynes, UK). KLHL7 expression was scored as none, weak, moderate or strong depending on the intensity of cytoplasmic staining (Fig. 1 ). Cytoplasmic expression was assessed, and H-scores were calculated using the proportion of stained cells (0-100%) and intensity scores (0, negative; 1, weak; 2, moderate; 3, strong) as previously described [28, 29] .
Statistical analysis
Statistical analysis was performed with SPSS v22.0 (IBM Corp., Armonk, NY, USA). The association of KLHL7 mRNA expression and CNA was assessed using the Kruskal-Wallis test. The significance of differences in CNA and mRNA expression in tumours stratified by PAM50 subtype, size, lymph node metastasis grade and histological grade was determined using the Chisquared and Fisher's exact tests. For analysis, tissue samples were assigned to high-and low-expression groups using the median mRNA expression level as the cut-off. For KLHL7 expression, the cut-off was an H-score of 90 determined by X-Tile plotting (X-Tile Bioinformatics Software, Yale University, version 3.6.1), with the samples stratified to high and low groups based on patient outcome. For the association between KLHL7 and prognosis, Kaplan-Meier survival curves of 10-year breast cancer-specific survival (BCSS) were plotted, and significance was determined by the logrank test. As the patients in the Nottingham primary series were followed up for at least 10 years, BCSS was defined as the interval from surgery to death from breast cancer. In univariate and multivariate analyses of clinicopathological factors and KLHL7 expression and prognosis, 95% confidence interval (CI) values were determined using the Cox proportional hazards regression model.
Results
KLHL7 Copy number alterations and mRNA expression
A total of 150 of 1980 patients (7.6%) had a copy number gain, whereas 23 (1.7%) had a loss of KLHL7. KLHL7 mRNA expression was significantly higher in samples with CNA gain than in CNA neutrals (p < 0.0001). The expression was significantly lower in tumours with CNA loss than in CNA-neutral tissues (p = 0.042). KLHL7 CNAs were significantly correlated with molecular subtype (p < 0.0001); KLHL7 gain was higher in HER2-enriched tumours, whereas KLHL7 loss was more frequent in basal-like tumours than in other subtypes (Table 1) . High KLHL7 mRNA expression was significantly related with high histological grade (p = 0.010) and molecular subtypes (p < 0.0001), and high expression in HER2-enriched tumours and low in basal-like tumours (Table 1) .
Although the association between KLHL7 CNA and mRNA expression and outcome was not significant in the METABRIC series ( Supplementary Fig. 3) , it was significant in the larger series of the Breast Cancer GeneExpression Miner v4.0 with an association between high KLHL7 mRNA expression and shorter survival [hazard ratio (HR) = 1.3; p < 0.0001; Fig. 2a ]. 
KLHL7 protein expression
In full-face sections, the expression of KLHL7 protein was variable in the different components of tissues with increased expression in invasive tumours cells than DCIS and normal parenchymal cells (Fig. 3) . Fibroblasts and lymphocytes in the mammary stroma adjacent to the cancer cells showed negative to weak staining. In normal glandular epithelium, the reactivity of IHC was absent to weak and the reactivity of myoepithelial cells tended to be higher than those of glandular cells. The reactivity of invasive cancer cells were higher compared to the intraductal malignant epithelial cells surrounding invasion. KLHL7 positivity was recognised in the cytoplasm of invasive cancer cells and the reactivity was substantially stronger compared to normal mammary gland cells if positive. Focal weak to moderate nuclear immunoreactivity was seen in the tumour cells simultaneously with cytoplasmic staining.
Clinicopathological and prognostic significance of KLHL7 protein expression
Of the 917 patients, 407 (44.4%) had tumours with low KLHL7 expression, whereas 510 (55.6%) had tumours with high expression (H-score ≥ 90). KLHL7 expression was positively correlated with histological grade (p = 0.0002) and LVI status (p = 0.030) but inversely correlated with ER status (p = 0.015, Table 2 ). High KLHL7 expression was significantly related with molecular subtypes (p = 0.026), especially HER2-positive and triple-negative breast cancer (TNBC) classes (Table 2 ). High KLHL7 expression was significantly associated with high expression of PIK3CA (p = 0.044) and p53 (p = 0.002), but not pAkt expression ( Table 2) .
The 10-year BCSS of the subgroup with KLHL7 high expression was significantly shorter than that of the subgroup with KLHL7 low expression (HR 9.1; p = 0.0025; Fig. 2b ). Univariate analysis identified high KLHL7 In multivariate analysis including other prognostic variables, KLHL7 expression remained independently associated with poor prognosis (HR 1.3 ; p = 0.042; Table 3 ).
Discussion
KLHL7 forms a ubiquitin ligase complex and regulates ubiquitination [9, 10] ; however, there is a critical lack of knowledge of the targets of KLHL7 ubiquitination in breast cancer. In the present study, we revealed the significant association of KLHL7 expression with p53 suggesting that aberrant KLHL7 ubiquitination may be responsible for decreased p53 function. Several E3 ubiquitin ligases are thought to regulate p53 expression in cancer [30, 31] . The function of p53 has been known to play important role in genomic stability, cell cycling and apoptosis [32, 33] with p53 suppressing cell proliferation in breast cancer cells [34] [35] [36] . The function of p53 is also associated with activation of PI3K/Akt signalling pathway [37] . In a previous study, high p53 protein expression significantly correlated with high PIK3CA protein expression [24] . Activation of PI3K pathway is regulated by growth factors through transmembrane receptor [38] . The breast cancer with PIK3CA mutations has frequent aberrant activation of PI3K pathway [38] . Approximately 20-25% of breast cancer have PIK3CA mutations [39] . Previous studies suggest that breast cancer become resistant to treatment by activating the PI3K/Akt signalling pathway [40, 41] . Recent clinical trials indicated that PI3K inhibitor [42] and mTOR inhibitor [43] , which inhibit the activity of PI3K/Akt signalling pathway, were useful for the treatment of metastatic breast cancer patients. The current study indicates the positive relationship between KLHL7 and PIK3CA expression. Further functional studies are necessary to explore the association of aberrant ubiquitination caused by KLHL7 overexpression with PI3K/Akt signalling pathway activity in breast cancer.
LVI is involved in breast cancer metastasis and is a recognised prognostic factor [44] [45] [46] [47] . In this study, KLHL7 expression was significantly associated with positive LVI status, negative ER status and TNBC. KLHL7 is located at 7p15, which shows frequent copy number alteration in basal-like subtype [48] . A recent genetic analysis of TNBC cases identified mesenchymal and mesenchymal stem-like subtypes to be high expressers of epithelial mesenchymal transition (EMT) and cancer stem cell-related genes [49, 50] . Ubiquitination is thought to influence cancer stem cell-like properties in breast cancer, and E3 ligases may be active in cancer stem cell growth [8] . A recent study reported that the C-terminus of heat shock cognate 71 kDa (HSC70) interacting protein (CHIP), a ubiquitin ligase 1 3 present in the cytoplasm, inhibits cancer stem-like cell activity in breast tumours and suppresses proliferation and metastasis of cancer cells [51] . Reduced CHIP expression has also been associated with high histological grade, hormonal receptor negativity and poor prognosis in breast cancer [52] . Aberrant ubiquitination may be responsible for enhanced cancer stem cell-like functions and EMT of breast cancer cells underlying LVI and metastasis. KLHL7 positivity was recognised in the cytoplasm of invasive cancer cells. Although occasional cases showed nuclear staining, the number was small for reliable statistical analysis and the expression was weak to moderate and seen simultaneously with cytoplasmic staining. High cytoplasmic staining of KLHL7 was associated with poor outcome in breast cancer patients. Importantly, the association with poor outcome was independent of other prognostic variables. Although no association between KLHL7 CNA and outcome was identified in the META-BRIC cohort, the number of cases with CNA was limited with less than 2% showing copy number loss. Using the large cohort of Breast Cancer Gene-Expression Miner, the association between KLHL7 mRNA expression and outcome was highly significant.
Conclusions
KLHL7 expression was related with molecular subtypes of breast cancer at genomic, transcriptomic and proteomic levels, and was strongly correlated with poorly differentiated tumours with LVI and with expression of p53 and PIK3CA. KLHL7 may be released into the cytoplasm and ubiquitinate the proteins involved in oncogenic pathways with the other factors involved in PI3K pathway. This may explain at least in part why the cytoplasmic expression of KLHL7 is an indicator of aggressive features and poor outcome in breast cancer. 
